Spokane, Washington, June 17, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, today announced the addition of Dr. Renuka Kulkarni, MD, as Chief Medical Officer (CMO). A physician scientist with over 20 years of experience in surgical and digital pathology, Dr. Kulkarni will join the team in guiding Gestalt’s product direction and clinical usability. Dr. Kulkarni brings a rare blend of diagnostic precision and scientific innovation to the organization. Her expertise in breast pathology, immunomarkers, machine learning, and image analysis strengthens Gestalt’s mission to revolutionize diagnostic workflows and clinical decision-making through technology. “Renuka’s addition signals our deepening investment in the future of pathology,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “Her leadership and experience at the intersection of clinical insight, AI, and enterprise lab operations will ensure our solutions continue to serve both pathologists and the patients they care for.” Before joining Gestalt, Dr. Kulkarni played a pivotal role in developing one of the earliest digital pathology programs at a leading full-service reference laboratory. Her extensive hands-on experience with Gestalt’s solutions, as a customer and direct user for four years, along with image analysis platforms, and combined with her understanding of real-world lab operations, positions her to help bridge the clinical and commercial realms—ensuring the scalability and impact of Gestalt’s solutions. As CMO, Dr. Kulkarni will help shape the development of next-generation diagnostic tools, supporting Gestalt’s mission to enhance diagnostic accuracy, efficiency, and interoperability across health systems worldwide. “I’m honored to join Gestalt at such a transformative moment in digital pathology,” said Dr. Kulkarni. “Together, we have the opportunity to shape solutions that truly serve pathologists and ultimately improve outcomes for patients everywhere.” About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

Date : Wednesday, May 21, 2025 Time : 1:45 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Session Title : The Long-Term Advantages of Digital Pathology are Only Realized Through True Interoperability We’re proud to announce that Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, and Sumie Edwards (ARUP) will take the stage at the 2025 Pathology Informatics Summit to share key insights into the critical role of interoperability in digital pathology. In this featured session, Lisa-Jean will explore: Why interoperability is the linchpin for scalable, future-ready digital pathology programs How health systems can unlock long-term value and efficiency through seamless integration Real-world considerations for IT infrastructure, workflow design, and cross-platform compatibility Her session will offer a strategic lens into how institutions can achieve meaningful digital transformation, not just implement new tools. About the PI Summit : The Pathology Informatics Summit is a premier annual event for professionals at the forefront of digital pathology, laboratory medicine, AI, and healthcare data innovation. It brings together leading physicians, researchers, and informaticists to discuss the rapidly evolving field. Mark your calendar for May 21 at 1:45 PM to hear Lisa-Jean share her vision for a more connected and impactful future in pathology.

Date : Thursday, May 22, 2025 Time : 9:00 AM – 12:00 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Panel Title : API Focus Session: Expert Panel on LDT Regulation Overhaul and Data Challenges in Pathology Informatics Join Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, for an important panel discussion at the 2025 Pathology Informatics Summit alongside top voices in the field of pathology informatics. This focus session will dive into: The impact of the FDA’s Final Rule on Laboratory Developed Tests (LDTs) Data governance, standardization, and access challenges for AI in pathology The urgent need for broadly sourced datasets to support the next generation of clinical AI models Panel Moderator : Ulysses Balis, MD Expert Panelists : Victor Brodsky, MD – Washington University School of Medicine, St. Louis Lisa-Jean Clifford – Gestalt Diagnostics Bruce Friedman, MD Ronald Jackups, MD, PhD – Washington University School of Medicine, St. Louis Amrom Obstfeld, MD, PhD – Children’s Hospital of Philadelphia Michelle Stoffel, MD, PhD – University of Minnesota J. Mark Tuthill, MD – Henry Ford Health System This dynamic session includes two panel discussions followed by open Q&A: The FDA’s Final Rule on LDTs The Growing Crisis of Limited AI Training Data in Pathology Why it matters : With regulatory landscapes shifting and AI innovation surging, this session offers a rare chance to hear from experts shaping the future of diagnostics, data ethics, and clinical technology adoption. Don’t miss this opportunity to learn from Lisa-Jean and fellow leaders who are building the next chapter of pathology informatics.

Spokane, Washington, April 28, 2025 – Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a $7.5 million Series A financing. The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest. Gestalt’s PathFlow® platform is used by leading healthcare, academic medical centers, and research organizations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. "PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise." This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company’s customer base, enhance AI capabilities, and pursue FDA clearance. This comes at a critical moment, with rising cancer rates and a declining number of practicing pathologists intensifying the need for scalable, digital-first diagnostic solutions. “We are incredibly grateful for the continued support from our investors,” Roark added. “This funding allows us to expand on the solid foundation we’ve built. We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.” Gestalt is at the forefront of a critical shift in diagnostic medicine, helping transform pathology from a manual, microscope-based process to a scalable digital solution leveraging artificial intelligence tools — like the digital transitions already seen in radiology and cardiology. The company’s platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable: Biomarker scoring to support the optimization of patient-therapy matching, Image and data analysis for disease progression studies, And the interoperability that enables pathologists access to valuable aides and insights that streamline their workflows, highlight areas of positivity and reduce missed diagnoses. With this Series A funding, Gestalt remains committed to expanding its impact through the deployment of its’ PathFlow software in healthcare, making high-quality, scalable pathology solutions more accessible to clinicians and researchers worldwide. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

March 21, 2025 – Mumbai, India and Spokane, Washington – AIRA Matrix, a leading innovator in AI-driven QC solutions, and Gestalt, an industry leader in IMS and digital pathology, have formed a strategic partnership to bring AIRA Matrix’s advanced AI solution, AIRAQC, to Gestalt's PathFlow. This collaboration marks a significant step toward enhancing diagnostic precision and efficiency in laboratories worldwide. AIRAQC, powered by cutting-edge artificial intelligence, streamlines quality control processes, enabling faster and more accurate analysis in pathology workflows. By integrating AIRAQC with Gestalt's workflows, pathologists will gain access to a seamless, AI-enhanced experience designed to optimize diagnostic decision-making. "We're thrilled to partner with Gestalt to expand the reach of AIRAQC and deliver transformative AI capabilities to pathology labs," said Marco Comianos, Head of Commercial Operations - US., AIRA Matrix. "This collaboration is a testament to our shared commitment to advancing pathology through innovation." “The partnership between AIRA Matrix and Gestalt represents a continued effort to drive progress in pathology by leveraging technology to meet evolving healthcare needs. Together, our companies aim to empower laboratories with state-of-the-art tools that improve diagnostic accuracy, quality and meaningful metrics from the start of the diagnostic process” says Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. About AIRA Matrix: Delivers artificial intelligence solutions for healthcare and life sciences applications. Our innovative products and services drive efficiency, enhance diagnostic accuracy, and provide data-driven insights from digitally scanned images. Our comprehensive AI-driven suite for drug discovery and development, streamlines pre-analytical quality control, facilitates tissue triage, and optimizes safety and efficacy assessments, accelerating breakthrough discoveries. Our healthcare portfolio offers diagnostic, prognostic, and predictive tools that facilitate risk stratification and enable personalized therapy planning, thus improving treatment outcomes., visit www.airamatrix.com. About Gestalt Diagnostics: Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable experience where it matters most. *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.

March 21, 2025 – Spokane, Washington – Gestalt, a leader in AI driven digital pathology solutions, and DLS Pathology Services, a reseller and consultation company providing expert direction on digital adoption and services are excited to announce a global reseller partnership. This collaboration brings Gestalt’s acclaimed digital platform directly to pathologists and healthcare entities in Australia and other territories. This reseller agreement continues Gestalt’s expansion into other countries through the locally focused expertise and experience of DLS Pathology Services. In this arrangement, DLS will be providing the sales and first line support of Gestalt’s digital pathology capabilities, ensuring that pathologists have the ability to leverage their consultations for pathology as a service provider and support. "We are excited to join forces with DLS Pathology Services to bring our industry leading digital pathology solutions to a wider global audience," said Lisa-Jean Clifford, COO & Chief Strategy Officer, Gestalt. "This partnership enables us to combine our innovative platform with DLS's local expertise, ensuring pathologists in Australia and beyond have the tools and support they need to provide exceptional diagnostic services.” “Gestalt provides the ideal platform for providing digital pathology services. Its ability to host and stream DICOM images at low-cost, with an intuitive interface for pathologists, helps us service clients at any scale”, says Dr. Jeremy Parry, Director, DLS Pathology Services. “I have been in the digital pathology business for more than a decade and tried pretty much all the Cloud platforms out there. With its speed, user-friendly interface and innovative use of DICOM, Gestalt is the best of the lot.” For more information about this partnership and the respective solutions, please visit Gestalt at booth #934 during USCAP March 23-26, 2025. About Gestalt Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. About DLS Pathology Services Our mission is to support and develop local pathology services, no matter what the budget or location. Recent progress in digital technologies means that no pathology service should be limited by remote geographical location, lack of local support, limited budgets or the shortcomings of traditional glass-slide (analogue) pathology workflows. At DLS Pathology Services, we believe that every medical service, with the appropriate support, can grow and flourish to support the needs of its local community. DLS stands for Deep Learning Solutions which underlines the Company's aim of developing and utilizing deep-learning and other machine applications as much as possible for the benefit of clients. To learn more, visit www.dlspath.com . *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.

March 19, 2025 – Spokane, Washington and Paris, France – Gestalt, a leader in digital pathology innovation, and Primaa , a MedTech pioneer specializing in AI-based dermatopathology solutions, are thrilled to announce a strategic partnership. This collaboration brings Primaa’s cutting-edge AI technology for skin cancer diagnosis directly into Gestalt’s acclaimed PathFlow platform. Together, they aim to create seamless workflows for pathologists while upholding the highest levels of diagnostic precision and patient safety. Gestalt’s PathFlow is known for its versatility, supporting primary diagnoses*, education, resident training, and research workflows. By integrating Primaa’s advanced AI algorithms, the platform now empowers pathologists with enhanced tools for detecting and quantifying tumor biomarkers in skin tissues. This integration allows pathologists to utilize AI-driven algorithms that detect critical biomarkers in skin lesions. Through the combined offering can automatically identifiy lesion types—including melanoma, squamous cell carcinoma, and basal cell carcinoma—and provides detailed measurements of lesion dimensions and margins. The solution also detects automatically all perineural invasions and all mitosis objects in the melanoma. Additionally, the system prioritizes high-risk cases for immediate review, ensuring timely and accurate diagnosis. "Partnering with Primaa to integrate their skin AI technology into PathFlow underscores our dedication to providing pathologists with state-of-the-art tools,” said Lisa-Jean Clifford, COO & Chief Strategy Officer of Gestalt. “This partnership represents a pivotal advancement in enhancing workflow efficiency and delivering superior patient care related to skin cancer." Fanny Sockeel, CEO at Primaa, added, “Our collaboration with Gestalt, a leader in digital pathology, marks a significant step toward integrating AI seamlessly into pathologists’ workflows. Together, we aim to empower pathologists with cutting-edge technology that supports faster, more precise diagnoses - ultimately improving patient outcomes.” For more information about this partnership and the respective solutions, please visit Gestalt at booth #934 and Primaa at booth #820 during USCAP March 23-26, 2025. About Gestalt: Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. About Primaa: Founded in 2018, Primaa is a pioneering MedTech company dedicated to transforming cancer diagnostics through Artificial Intelligence. Our advanced platform leverages cutting-edge image analysis and deep learning to enhance the accuracy and efficiency of biomarkers detection for major cancers. By empowering pathologists with automated and precise insights, Primaa is helping to drive more personalized treatment strategies and ultimately improving patient outcomes. www.primaalab.com *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.

Dear Clients, Partners, and Friends, As we close out 2024, I want to take a moment to reflect on the incredible milestones we’ve achieved together. At Gestalt Diagnostics, we remain committed to advancing digital pathology and supporting our clients in delivering the highest level of patient care. This year has been a remarkable journey, and I’m proud to share some highlights with you. Innovations and Product Enhancements This year, we introduced the PathFlow® AI Algorithm Evaluator , a tool enabling labs to test and integrate multiple AI algorithms seamlessly into workflows, driving precision and efficiency. We also expanded our Digital Pathology Education Module to include proficiency testing, credentialing, and management tools, empowering professionals with critical resources for growth. Thought Leadership and Industry Contributions Our team shared valuable insights through leading journals and platforms: Published in Medical Laboratory Observer on preparing labs for automation with digital pathology and AI . Shared findings on biomarkers in prostate cancer diagnosis and digital pathology adoption in MLO. Hosted engaging discussions like the Digital Pathology Today Podcast: A Fresh Start for Pathology and a Q&A on enhancing clinical labs through advanced data analytics. Strategic Partnerships and Collaborations We strengthened our partnerships globally, adding several AI integrations into PathFlow®. Notably, we were selected by Optum (Change Healthcare) as their digital pathology partner, complementing their Enterprise Imaging Suite. We also expanded into Africa with DataPathology , marking a key step in our international growth. Recognition and Advisory Excellence This year, we welcomed Dr. J. Mark Tuthill to our Strategic Advisory Board, whose expertise has already brought immense value to our mission. Our leadership team also took on influential roles, with elections as President-Elect of the API and as Co-Chairs of DICOM Working Group 26, further contributing to global pathology standards. Global Impact and Market Growth Gestalt celebrated substantial growth, increasing our customer base and revenue while earning accolades for innovation and market expansion. These achievements reflect our dedication to pushing the boundaries of digital pathology and delivering meaningful results for labs worldwide. As we step into 2025, I am filled with excitement and gratitude. Thank you for your trust, collaboration, and commitment to advancing pathology alongside us. Together, we are shaping the future of this vital field. Wishing you success and innovation in the year ahead,

Featured in CAP TODAY December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared. “It’s an ongoing conversation and foregone conclusion that laboratories will be going digital,” said Lisa-Jean Clifford, president-elect of the Association for Pathology Informatics.